+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021

  • PDF Icon

    Drug Pipelines

  • 44 Pages
  • June 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5359603
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively.

Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
  • Report Coverage

Pulmonary Embolism - Overview
Pulmonary Embolism - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies

Pulmonary Embolism - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Pulmonary Embolism - Companies Involved in Therapeutics Development
  • Acticor Biotech SAS
  • Bio-Synectics Inc
  • China Resources Emde Biological Pharmaceutical Co Ltd
  • Indiana Lysis Technologies LLC
  • Kolmar Korea Co Ltd
  • Les Laboratoires Servier SAS
  • Supergene LLC
  • Tasly Pharmaceutical Group Co Ltd
  • Techfields Pharma Co Ltd
  • Tianjin Pharmaceuticals Group Co Ltd
  • Verseon Corp

Pulmonary Embolism - Drug Profiles
BS-112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Drugs for Pulmonary Embolism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

glenzocimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

KKM-183A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

reteplase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

S-62798 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Staphylokinase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

TF-0023 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

urokinase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

VE-2851 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Zifa-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Pulmonary Embolism - Dormant ProjectsPulmonary Embolism - Discontinued ProductsPulmonary Embolism - Product Development Milestones
Featured News & Press Releases
  • Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs
  • Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition
  • Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Pulmonary Embolism, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pulmonary Embolism - Pipeline by Acticor Biotech SAS, 2021
  • Pulmonary Embolism - Pipeline by Bio-Synectics Inc, 2021
  • Pulmonary Embolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2021
  • Pulmonary Embolism - Pipeline by Indiana Lysis Technologies LLC, 2021
  • Pulmonary Embolism - Pipeline by Kolmar Korea Co Ltd, 2021
  • Pulmonary Embolism - Pipeline by Les Laboratoires Servier SAS, 2021
  • Pulmonary Embolism - Pipeline by Supergene LLC, 2021
  • Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
  • Pulmonary Embolism - Pipeline by Techfields Pharma Co Ltd, 2021
  • Pulmonary Embolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2021
  • Pulmonary Embolism - Pipeline by Verseon Corp, 2021
  • Pulmonary Embolism - Dormant Projects, 2021
  • Pulmonary Embolism - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Pulmonary Embolism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Acticor Biotech SAS
  • Bio-Synectics Inc
  • China Resources Emde Biological Pharmaceutical Co Ltd
  • Indiana Lysis Technologies LLC
  • Kolmar Korea Co Ltd
  • Les Laboratoires Servier SAS
  • Supergene LLC
  • Tasly Pharmaceutical Group Co Ltd
  • Techfields Pharma Co Ltd
  • Tianjin Pharmaceuticals Group Co Ltd
  • Verseon Corp